Clinical trial
Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of…
NCT00434239 · Peter MacCallum Cancer Centre, Australia, Other · Unknown status
Key facts
| NCT number | NCT00434239 |
|---|---|
| Title | Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia |
| Official title | A Pilot Study of the Combination of Lenalidomide (Revlimid®) With Two Different Dose Levels of Short Term Administration of Recombinant Human Stem Cell Factor (rhSCF; Ancestim) for Myelodysplasia. |
| Lead sponsor | Peter MacCallum Cancer Centre, Australia, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Unknown status |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Myelodysplasia |
| Intervention type | Drug |
| Interventions | Lenalidomide + Ancestim |
| Enrollment | 25 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2014 |
| First posted | Feb 13, 2007 |
| Last update posted | Jan 10, 2013 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: